JERUSALEM--(BUSINESS WIRE)--On its quarterly earnings conference call today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced the following updates to its expectations for full year 2011.
For the full year 2011, the Company now expects net sales to be between $18.3 billion to $18.6 billion, compared to the previous estimated range of $18.5 billion to $19 billion. Non-GAAP diluted earnings per share is expected to be between $4.92 to $5.02, compared to the previous estimated range of $4.90 to $5.20. The new full year estimate includes a non-GAAP diluted earnings per share contribution of approximately $0.15 from the consolidation of the Cephalon acquisition.
